Equities

Themis Medicare Ltd

THEMISMED:NSI

Themis Medicare Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)202.75
  • Today's Change-3.80 / -1.84%
  • Shares traded24.44k
  • 1 Year change+37.46%
  • Beta1.4160
Data delayed at least 15 minutes, as of May 31 2024 10:48 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.

  • Revenue in INR (TTM)3.82bn
  • Net income in INR435.24m
  • Incorporated1969
  • Employees996.00
  • Location
    Themis Medicare Ltd11/12 Udyog Nagar, S V Road, Goregaon (West)MUMBAI 400104IndiaIND
  • Phone+91 2 267607080
  • Fax+91 2 228746621
  • Websitehttps://www.themismedicare.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Beta Drugs Ltd2.56bn347.57m11.56bn315.0033.258.1425.254.5236.1536.15266.28147.681.244.443.728,126,721.0016.85--25.36--41.88--13.58--1.4318.210.098--23.54--23.73------
Zota Health Care Ltd1.80bn-143.48m12.32bn338.00--13.34214.446.82-5.59-5.5970.4034.810.93412.026.55---7.42-1.38-10.54-1.8546.4336.48-7.95-1.330.7851-2.620.5143--28.9616.08-148.54--39.850.00
Windlas Biotech Ltd6.31bn581.87m13.15bn1.05k22.622.9218.352.0827.9427.94302.99216.331.095.794.99--10.07--13.50--37.21--9.22--2.1558.580.008--22.97--36.51------
Ngl Fine Chem Ltd3.39bn413.43m13.85bn343.0033.505.2726.154.0966.9266.92548.61425.111.054.514.36--12.8715.0616.6119.5853.1846.7912.2013.151.9630.640.12183.0621.7917.20101.5815.4714.490.00
Hester Biosciences Ltd3.05bn188.89m15.30bn693.0072.265.2439.915.0224.8924.89392.38343.010.45721.203.85--3.186.154.007.6968.5268.836.9512.831.311.840.446623.2714.4511.33-29.06-14.591.49-11.42
SMS Pharmaceuticals Ltd7.09bn498.26m16.77bn1.10k33.633.1320.782.365.895.8983.8463.360.74132.183.69--5.145.437.417.3329.8332.676.947.870.9053.630.34366.5935.868.81805.824.478.419.86
Themis Medicare Ltd3.82bn435.24m18.66bn996.0042.954.9433.464.894.724.7241.4141.030.70671.962.36--8.0611.1211.0716.4664.1961.4911.4014.961.44--0.20238.287.7415.75-23.51--26.73--
Amrutanjan Health Care Ltd4.21bn449.73m19.98bn575.0044.586.9339.154.7415.5115.51145.0099.851.167.3410.41--12.3416.2215.0920.1249.7153.3010.6813.233.82291.990.00623.3710.9610.7112.9012.4626.9316.43
Solara Active Pharma Sciences Ltd13.26bn-5.67bn20.07bn2.36k--1.75--1.51-145.25-145.25339.41239.080.5051.752.99---21.60-2.44-39.08-3.8439.2843.38-42.77-4.490.3549-1.890.5192---10.73-1.45-2,458.12---4.81--
Suven Life Sciences Ltd116.93m-1.05bn20.19bn132.00--7.48--172.70-4.82-4.820.535912.380.0347--11.17---31.19-46.46-32.37-50.52-----898.63-787.6118.94-849.160.0026---13.64-47.2311.15------
RPG Life Sciences Limited5.82bn876.60m23.62bn1.17k26.956.3022.564.0653.0153.01351.99226.651.251.8813.45--18.8116.0725.1021.7768.3064.0415.0611.991.50246.840.0029.2713.5012.0129.6051.9828.6046.14
Morepen Laboratories Ltd16.90bn961.60m23.64bn1.65k24.602.7918.171.401.881.8833.1116.581.414.455.74--8.047.9011.5013.3437.1533.655.725.491.5933.730.0331--19.2517.08148.6327.2247.03--
Dishman Carbogen Amcis Ltd25.80bn-1.54bn25.20bn1.30k----17.100.9767-9.84-9.84164.35--------19,919,850.00--0.4699--0.566576.9374.36-5.981.82---0.1245--202.7612.727.32-265.46--21.54--
SeQuent Scientific Ltd13.70bn-358.69m25.77bn478.00--3.9280.701.88-1.45-1.4556.2726.370.89252.194.05---1.931.09-3.271.7644.5342.74-2.161.180.76020.13760.4062---3.605.6870.40--6.96--
Data as of May 31 2024. Currency figures normalised to Themis Medicare Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024396.000.00%
Data from 15 May 2024 - 15 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.